T-cell lymphomas that are positive for CD20 are very rare and most reported cases have demonstrated an aggressive clinical course. An unusual case of a 57year old female who presented with recurrent enlarged lymph nodes for 12 years is reported. The lymph nodes from both 1995 and 2007 showed effacement of the lymph node architecture by a diffuse and dense infiltrate of small lymphoid cells. In terms of T-and B-cell markers, these small lymphoid cells were immunohistochemically positive for CD2, CD3, CD5, CD43, CD45RO and CD20, and were negative for PAX5, CD79a and cyclin D1. Molecular genetic analysis showed Tcell receptor-g chain gene rearrangement. Recognition of this type of CD20-positive T-cell lymphoma is important for ensuring a correct diagnosis so that the patient can be offered the most appropriate therapy. The indolent behaviour of the present case is unusual and awaits further clinical follow-up and laboratory investigation.
Introduction
The current World Health Organization classification for non-Hodgkin's lymphoma (NHL) has incorporated immunophenotyping as an integral part of lymphoma diagnosis. 1 The NHLs are broadly divided into T-cell and B-cell types based on their immunophenotyping by immunohistochemistry or flow cytometry. 2 The markers, CD20 and CD3, are the most widely used for B-and T-cell lineage, respectively, but coexpression of various B-and T-cell markers is commonly encountered in precursor T-cell lymphoblastic lymphoma and in low-grade B-cell lymphomas such as small lymphocytic lymphoma/chronic lymphocytic leukaemia and mantle cell lymphoma. 1 The expression of CD20 in T-cell lymphoma is, however, quite rare 2 -4 and this type of lymphoma always pursues an aggressive clinical course. 5, 6 A case of CD20-positive T-cell lymphoma with an indolent clinical course is reported.
Case report
A 57-year old female presented with recurrent enlarged lymph nodes for 12 years. She noted bilateral enlargement of cervical lymph nodes in the summer of 1995. Cervical lymph node biopsy was performed in a local hospital and the diagnosis was 'small B-cell non-Hodgkin's lymphoma'. The patient was treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy and radiotherapy during the subsequent years. Indolent T-cell lymphoma expressing CD20 Lymphocytosis and thrombocytopenia were noted in 2005 and a bone marrow biopsy revealed small lymphoid cells infiltrated in her bone marrow. The patient complained of recurrent epistaxis in January 2007. Physical examination revealed enlarged lymph nodes in the axilla and inguinal areas. Bone marrow and inguinal lymph node biopsies were performed. Biopsy specimens together with a paraffin block of a cervical lymph node resected 12 years previously were sent to our laboratory for examination.
The lymph nodes from both 1995 and 2007 showed the same changes. There was effacement of the lymph node architecture by a diffuse and dense infiltrate of small lymphoid cells. The cytoplasm was pale, with irregularly folded or cerebriform nuclei and inconspicuous nucleoli (Fig. 1A) . The bone marrow specimen from 2007 also showed infiltration with abundant small lymphoid cells with the same morphology.
In terms of T-and B-cell markers, immunohistochemical studies revealed that the small lymphoid cells were positive for CD20 ( Fig. 1B) , CD2, CD3 (Fig. 1C ), CD45RO, CD5 and CD43, but they were negative for CD79a ( Fig. 1D ), CD10, CD7, CD56, CD23, B-cell lymphoma 2 (Bcl-2), TIA1, perforin, granzyme B and cyclin D1. The small lymphoid cells infiltrated into the bone marrow were also positive for CD20, CD2, CD3, CD45RO and CD5, and were negative for CD79a, CD10, CD7, terminal deoxynucleotidyl transferase and myeloperoxidase. Repeated immunohistochemical staining undertaken at the Department of Pathology, Queen Elizabeth Hospital (Hong Kong) showed that the tumour cells were positive for CD2, CD3, CD5, CD43, CD45RO and CD20, and were negative for PAX5, CD79a and cyclin D1.
Polymerase chain reactions were performed on the lymph node specimens taken in 1995 and 2007. T-cell receptor (TCR)-γ chain gene rearrangement was demonstrated in the lymph node specimens.
Discussion
The B-cell marker, CD79a, can be expressed in precursor B-cells in the bone marrow and is retained throughout B-cell differentiation. 2 PAX5 is a B-cell specific transcription factor and is expressed in B-cells from an early stage of B-cell development through to mature B cells. 7 As a result, CD79a and PAX5 are considered to be two highly specific B-cell markers. In the present case, there was positive staining for multiple T-cell markers, in particular CD2 and CD3. The only B-cell marker that was positive was CD20, while the specific B-cell markers CD79a and PAX5 were negative. Based on morphology together with the immunohistochemical results, this case was diagnosed as a CD20positive peripheral T-cell lymphoma.
The expression of CD20 on T-cells may be seen in either normal, reactive, or neoplastic processes. For example, Algino et al. 8 reported that a small population of normal bone marrow T-lymphoid cells can coexpress CD3 and CD20. Quintanilla-Martinez et al. 9 investigated a CD20-positive T-cell population in the peripheral blood of healthy donors. They found that a mean of 3.50% (range 0.94 -11.90%) of peripheral blood T-cells co-expressed low levels of CD20 and CD3. 9 The authors concluded that CD20 expression by T-cell lymphomas may represent neoplastic transformation of a normal subset of CD20-positive T-cells rather than aberrant antigen expression by neoplastic cells. Hultin et al. 10 also found that a small subset of human T-cells expressed low levels of CD20.
To avoid misdiagnosis, a large panel of monoclonal antibodies has been suggested for immunophenotyping. 11 The present case was initially misdiagnosed as 'small B-cell NHL' because only a small panel of monoclonal antibodies was used. Sun et al. 11 reported that flow cytometry was superior to immunohistochemistry in indentifying B-cell marker-positive T-cell lymphomas because flow cytometry can identify dual immunostaining of B-and T-cell markers. Application of antigen receptor gene rearrangements for determining the B-or Tcell derivation of a given lymphoma may aid in the correct diagnosis of CD20-positive T-cell lymphoma. 2 It is very difficult to diagnose T-cell lymphomas without evidence of clonal TCR-γ or -β chain gene rearrangements. The CD20-positive cases with ambiguous phenotypes may require genotypic studies for precise lineage assignment. Recognition of this type of CD20-positive T-cell lymphoma is important for making a correct diagnosis, which can then inform the choice of adequate therapy for patients. Hirata et al. 12 recently reported on the treatment of CD20-positive peripheral T-cell lymphoma with rituximab.
One unique feature of the present case was the indolent clinical course. Peripheral T-cell lymphoma is generally an aggressive tumour. Overall, 11/26 reported cases of CD20-positive T-cell lymphoma have expressed a cytotoxic T-cell phenotype. 5, 6 Patients often respond poorly to therapy, relapses are frequent, and the overall and failure-free survival rates at 5 years are about 20 -30%. 13 Although the patient reported in the present study had experienced recurrent disease several times and the lymphoid cells had infiltrated into her bone marrow, the disease had a somewhat indolent course because the patient has at least a 12-year history of lymphoma and remains alive. Some T-cell lymphomas have been reported to pursue indolent clinical behaviour, although the clinical behaviour of the present case is unusual. Rahemtullah et al. 14 15 reported a case of primary T-cell lymphoma of the gastrointestinal tract that had regressed spontaneously and recurred numerous times over a 9-year period without treatment.
In summary, the case of a CD20-positive T-cell lymphoma with an indolent clinical course was reported. The aberrant expression of CD20 in this T-cell lymphoma was most likely incidental but could be indicative of a normal antigenic phenotype not previously recognized. The biological behaviour of this case awaits further clinical follow-up and laboratory investigation.
